Shattuck Labs (NASDAQ:STTK) Trading Up 8.4% - Here's Why

Key Points

• Shares rose 8.4% to $7.61 on Thursday with ~685,924 shares traded, about 4% above the stock's average daily volume.
• Analyst sentiment is broadly positive with a consensus rating of "Moderate Buy" and an average target of $10.50 (six Buys, one Hold, one Sell), including notable targets from Needham ($25) and Piper Sandler ($15).
• Shattuck is a clinical‑stage biotech developing an immunotherapeutic fentanyl vaccine; it has a market cap of ~$528M, reported EPS of ($0.12) last quarter (meeting estimates) but missed revenue expectations, and analysts project a -1.48 EPS for the year.

Shares of Shattuck Labs, Inc. (NASDAQ:STTK - Get Free Report) were up 8.4% during trading on Thursday . The company traded as high as $7.59 and last traded at $7.61. Approximately 685,924 shares traded hands during trading, an increase of 4% from the average daily volume of 660,292 shares. The stock had previously closed at $7.02.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on STTK shares. Piper Sandler started coverage on shares of Shattuck Labs in a research note on Wednesday, January 28th. They set an "overweight" rating and a $15.00 target price for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Shattuck Labs in a research note on Thursday, January 22nd. Wedbush upped their price objective on shares of Shattuck Labs from $4.00 to $8.00 and gave the company an "outperform" rating in a research note on Friday, March 6th. Needham & Company LLC started coverage on shares of Shattuck Labs in a research note on Friday, March 6th. They issued a "buy" rating and a $25.00 price objective for the company. Finally, Citigroup upped their price objective on shares of Shattuck Labs from $4.00 to $7.00 and gave the company a "neutral" rating in a research note on Friday, March 13th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $10.50.

Shattuck Labs Price Performance

The company has a market cap of $527.76 million, a price-to-earnings ratio of -9.54 and a beta of 1.28. The firm's 50 day simple moving average is $5.09 and its 200-day simple moving average is $3.61.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). The company had revenue of ($1.00) million during the quarter, compared to analyst estimates of $0.17 million. On average, analysts forecast that Shattuck Labs, Inc. will post -1.48 EPS for the current year.

Institutional Investors Weigh In On Shattuck Labs

Several hedge funds have recently made changes to their positions in STTK. Turtle Creek Wealth Advisors LLC acquired a new stake in shares of Shattuck Labs during the third quarter worth about $29,000. Virtu Financial LLC acquired a new stake in shares of Shattuck Labs during the third quarter worth about $38,000. AQR Capital Management LLC boosted its stake in shares of Shattuck Labs by 265.4% during the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company's stock worth $41,000 after buying an additional 31,355 shares during the period. Qube Research & Technologies Ltd acquired a new stake in shares of Shattuck Labs during the second quarter worth about $44,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Shattuck Labs during the third quarter worth about $46,000. Institutional investors and hedge funds own 58.74% of the company's stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc NASDAQ: STTK is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company's lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.